Tags: Cancer | leukemia | AG-221 | drug | remission | sloan

New Leukemia Drug Shows Dramatic Response

By    |   Tuesday, 09 December 2014 10:05 AM

A new targeted type of cancer therapy produced dramatic results for patients with a certain type of advanced leukemia, a study showed.
 
About 15 percent of patients with acute myeloid leukemia have a genetic mutation in their IDH2 gene, which makes a protein that that prevents immature white blood cells from developing into healthy cells. The defective cells accumulate, crowding out normal cells and this leads to the development of the blood cancer.
 
Researchers at Memorial Sloan Kettering Cancer Center gave the drug, called AG-221, to 45 patients with this type of leukemia. AG-221 is an investigational medication that blocks mutated IDH2 protein, effectively allowing the immature white blood cells to develop normally. All the patients had advanced disease that had relapsed or was unresponsive to prior therapy.
 
The overall response rate was 56 percent; 15 patients achieved complete remission and 10 patients partial remission. In addition, the response has been sustained and is ongoing. Patients in remission have stayed in remission.  
 
The drug is only in early testing stages, but Eytan M. Stein, M.D., the lead investigator, said the medication “has the potential to transform the treatment of leukemia.”
 
 
 

© 2019 NewsmaxHealth. All rights reserved.

   
1Like our page
2Share
Health-News
A new targeted type of cancer therapy produced dramatic results for patients with a certain type of advanced leukemia, a study showed. About 15 percent of patients with acute myeloid leukemia have a genetic mutation in their IDH2 gene, which makes a protein that that...
leukemia, AG-221, drug, remission, sloan
190
2014-05-09
Tuesday, 09 December 2014 10:05 AM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved